Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
The suggested activity of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and 5-fluorouracil as single agents in the treatment of advanced prostate and/or transitional cell carcinoma led us to examine the response to these drugs used in combination. Combination chemotherapy has the theoretical advantages of additive antitumor effect without additive toxicity to the host. One of 8 patients with Stage D, endocrine unresponsive prostatic adenocarcinoma achieved an objective response. There were five stable and one subjective responses. Only 1 patient showed progression during the initial six-week trial. Two of 3 patients with transitional cell carcinoma had an objective response. This three-drug combination was well tolerated by elderly patients and on the basis of this small series further trials are warranted.
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D004317:Doxorubicin; D003520:Cyclophosphamide; D000135:Acid Phosphatase; D005472:Fluorouracil